Entering text into the input field will update the search result below

Sanofi's Xenpozyme gets approval in Japan for rare genetic disease

Mar. 28, 2022 6:23 AM ETSanofi (SNY) StockBy: Ravikash Bakolia, SA News Editor

Night Sanofi office building in Berlin, Germany.

Panama7/iStock Editorial via Getty Images

  • The Japanese Ministry of Health, Labor, and Welfare (MHLW) approved Sanofi's (NASDAQ:SNY) Xenpozyme (olipudase alfa) to treat adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
  • ASMD is a

Recommended For You

More Trending News

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi